Deutsche Bank
JUNO

Deutsche Bank’s Juno Therapeutics, Inc. JUNO Stock Holding History

Deutsche Bank’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-371,053
Closed -$17M – 5797
2017
Q4 		$17M Buy
371,053
+112,537
+44% +$5.61M 0.01% 1111
2017
Q3 		$11.6M Buy
258,516
+26,056
+11% +$888K 0.01% 1352
2017
Q2 		$6.95M Buy
232,460
+17,253
+8% +$426K 0.01% 1673
2017
Q1 		$4.77M Sell
215,207
-2,038
-0.9% -$43.7K ﹤0.01% 1703
2016
Q4 		$4.09M Sell
217,245
-222,153
-51% -$5.44M ﹤0.01% 1774
2016
Q3 		$13.2M Buy
439,398
+78,909
+22% +$2.45M 0.01% 1117
2016
Q2 		$13.9M Buy
360,489
+205,603
+133% +$8.53M 0.01% 1101
2016
Q1 		$5.9M Buy
154,886
+130,426
+533% +$4.54M ﹤0.01% 1631
2015
Q4 		$1.07M Sell
24,460
-2,373
-9% -$118K ﹤0.01% 2825
2015
Q3 		$1.09M Sell
26,833
-4,706
-15% -$206K ﹤0.01% 2882
2015
Q2 		$1.68M Buy
31,539
+23,162
+276% +$1.23M ﹤0.01% 2601
2015
Q1 		$507K Sell
8,377
-3,523
-30% -$171K ﹤0.01% 3287
2014
Q4 		$620K Buy
+11,900
New +$533K ﹤0.01% 3533

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Deutsche Bank's JUNO Position: Q1 2018 in Review

Deutsche Bank sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 371,053 shares — an estimated $17M sold.

Deutsche Bank first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $17M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Deutsche Bank reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Deutsche Bank sold 371,053 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $17M.
  • Deutsche Bank first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Deutsche Bank's Juno Therapeutics, Inc. position peaked at $17M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Deutsche Bank's 13F filing for Q1 2018, filed 15 May 2018.